NICE recommends nintedanib
The National Insitute for Health and Care Excellence (NICE) has recommended nintedanib as an option for treating idiopathic pulmonary fibrosis if the person has between 50% and 80% of their predicted forced vital capacity (FVC); the company provides nintedanib with the discount agreed in the patient access scheme; and treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period. Further details can be found on the NICE website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200655
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com